Cancer Clinical Trials in Philadelphia, Pennsylvania
332 recruitingPhiladelphia, Pennsylvania
Showing 1–20 of 332 trials
Recruiting
Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Breast Cancer
Canadian Cancer Trials Group2,140 enrolled485 locationsNCT03488693
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Hoffmann-La Roche316 enrolled32 locationsNCT04802759
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled299 locationsNCT06393374
Recruiting
Phase 1
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Breast Cancer
Novartis Pharmaceuticals48 enrolled25 locationsNCT05870579
Recruiting
Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled838 locationsNCT05812807
Recruiting
Phase 3
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Metastatic Breast Cancer
American Society of Clinical Oncology500 enrolled73 locationsNCT06377852
Recruiting
Phase 3
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled179 locationsNCT05232916
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled284 locationsNCT04862663
Recruiting
Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Breast Cancer
Celcuity Inc1,180 enrolled203 locationsNCT06757634
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951
Recruiting
Not Applicable
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Breast Cancer
University Hospital, Basel, Switzerland1,060 enrolled54 locationsNCT07140172
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2Phase 3
SHAPE Neoadjuvant Chemotherapy Response
Anatomic Stage III Breast Cancer AJCC v8Locally Advanced Breast Carcinoma
Kibo Nam200 enrolled3 locationsNCT04715958
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Metastatic Breast Cancer
Hoffmann-La Roche792 enrolled45 locationsNCT03424005
Recruiting
Phase 1
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Ovarian CancerCervical CancerEndometrial Cancer+7 more
Normunity AccelCo, Inc.150 enrolled9 locationsNCT07182149
Recruiting
Phase 1
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
Breast CancerGynecologic Cancers
Oregon State University60 enrolled3 locationsNCT07055854
Recruiting
Not Applicable
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Anatomic Stage 0 Breast Cancer AJCC v8Triple-Negative Breast CarcinomaInvasive Breast Carcinoma+4 more
Thomas Jefferson University80 enrolled1 locationNCT04959474
Recruiting
Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285
Recruiting
Phase 1
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Triple-Negative Breast CancerColorectal CarcinomaNon-small Cell Lung Cancer+4 more
Janux Therapeutics130 enrolled18 locationsNCT05783622
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444